ArticleMolecular therapy. Nucleic acids2025
Comparison of
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system.Nucleic acids research · 2026Article
- Variability in the circulation of cerebrospinal fluid: causes and clinical implications for intraventricular drug delivery.Frontiers in drug delivery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several antisense oligonucleotide (ASO) therapies are currently in clinical trials or approved for treatment of central nervous system (CNS) diseases. Achieving adequate distribution of systemically delivered ASOs in CNS tissues has been hindered by the blood-brain barrier (BBB). To overcome this, delivery of ASOs into cerebrospinal fluid (CSF) via intrathecal-lumbar (IT-L) injection has been utilized in the clinic. However, there is a gradient of distribution resulting in less drug in deep brain regions compared to cortical and spinal cord regions. An alternative direct-to-CSF route of administration, intracerebroventricular (ICV) administration, has been utilized to deliver other therapeutic modalities in the clinic. To our knowledge, a comprehensive comparison study of these two routes of delivery in large animals has not been done for ASOs. Therefore, we conducted a study to compare the ICV and IT-L route of delivery for the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.